Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
An estimated one-third of the world population is latently infected with Mycobacterium tuberculosis. These nonreplicating, dormant bacilli are tolerant to conventional anti-tuberculosis drugs, such as isoniazid. We recently identified diarylquinoline R207910 (also called TMC207) as an inhibitor of ATP synthase with a remarkable activity against replicating mycobacteria. In the present study, we show that R207910 kills dormant bacilli as effectively as aerobically grown bacilli with the same target specificity. Despite a transcriptional down-regulation of the ATP synthase operon and significantly lower cellular ATP levels, we show that dormant mycobacteria do possess residual ATP synthase enzymatic activity. This activity is blocked by nanomolar concentrations of R207910, thereby further reducing ATP levels and causing a pronounced bactericidal effect. We conclude that this residual ATP synthase activity is indispensable for the survival of dormant mycobacteria, making it a promising drug target to tackle dormant infections. The unique dual bactericidal activity of diarylquinolines on dormant as well as replicating bacterial subpopulations distinguishes them entirely from the current anti-tuberculosis drugs and underlines the potential of R207910 to shorten tuberculosis treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIGURE 4 ATP synthase is functional in dormant M. smegmatis . A , ATP synthesis activity in inverted membrane vesicles (50 𝛍 g/ml) from dormant M. smegmatis cultured for 10 days under Wayne O 2 depletion conditions. Positive control was membrane vesicles with buffer containing ADP, P i , and NADH, whereas negative control excluded NADH and Pi from the assay buffer. B , effect of R207910 on membrane potential in dormant M. smegmatis cultured for 10 days under Wayne O 2 depletion conditions. The membrane potential was measured using tetra-[ 3 H]phenylphosphonium bromide.](https://figures.cochat.ai/paper-figures/b01e7891765241e4a7d71c59f242a243/diarylquinolines-are-bactericidal-for-dormant-mycobacteria-as-a-result-of-figure-4.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationTranscriptional Adaptation of Mycobacterium tuberculosis within Macrophages
Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030846 · Cited by 1,420
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program
Voskuil, M. I., Schnappinger, D., Visconti, K. C., Harrell, M. I., Dolganov, G. M., Sherman, D. R., & Schoolnik, G. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030205 · Cited by 966
Muñoz-Elías, E. J., & McKinney, J. D. (2005) · Nature Medicine · doi:10.1038/nm1252 · Cited by 756
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Self-citationM. tuberculosis persistence, latency, and drug tolerance
Gomez, J. E., & McKinney, J. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.08.003 · Cited by 533
Cited by
The challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
Self-citationAdvances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
“Among the anti-TB agents discovered in the past decade, the diarylquinoline TMC207, which is active against metabolizing and non-growing cells, seems to be the leading candidat”
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
“Ofloxacin resistance 1 (6) 2 (10) 3 (8) Ethionamide resistance 2 ( 12 ) 1 (5) 3 (8)”
BackgroundInfluentialSelf-citationDiscovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3262 · Cited by 603
Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism
Adams, K. N., Takaki, K., Connolly, L. E., Wiedenhoft, H., Winglee, K., Humbert, O., Edelstein, P. H., Cosma, C. L., & Ramakrishnan, L. (2011) · Cell · doi:10.1016/j.cell.2011.02.022 · Cited by 530
“…not account for the recent finding that diarylquinolones, which are equally bactericidal for exponentially growing and dormant bacteria in culture (Koul et al., 2008), only shorten the time to cure from 6 months to 4 in the mouse model of TB, which features slowed bacterial growth (Ibrahim et…”
Alvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 373
“…Sponsor Class In vitro potency Mode of action Clinical trial status TMC 207 (Bedaquiline) Janssen Diarylquinoline 30–120 ng/ml (Andries et al., 2005; Koul et al., 2008) Targeting ATP synthase, inhibition of proton pumping activity (Huitric et al., 2010) III, FDA-approved (accelerated programme)…”
MethodNguyen, N.-Y. T., Grelling, N., Wetteland, C. L., Rosario, R., & Liu, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-34567-5 · Cited by 357
Koul, A., Vranckx, L., Dhar, N., Göhlmann, H. W. H., Özdemir, E., Neefs, J.-M., Schulz, M., Lu, P., Mørtz, E., McKinney, J. D., et al. (2014) · Nature Communications · doi:10.1038/ncomms4369 · Cited by 293
Self-citationAntibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Oligomycin Frames a Common Drug-Binding Site in the ATP Synthase
Symersky, J., Osowski, D., Walters, D. E., & Mueller, D. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207912109 · Cited by 269
“Recently, the drug R207910 (TMC207) has been identified that is effective against Mycobacterium tuberculosis (25, 26).”
BackgroundGengenbacher, M., Rao, S. P. S., Pethe, K., & Dick, T. (2010) · Microbiology · doi:10.1099/mic.0.033084-0 · Cited by 260
“tuberculosis (Koul et al., 2008; Rao et al., 2008).”
BackgroundInfluentialHypoxia: a window into Mycobacterium tuberculosis latency
Rustad, T. R., Sherrid, A. M., Minch, K. J., & Sherman, D. R. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01325.x · Cited by 252
“…have identified NAD synthesis, maintenance of the proton-motive force and ATP synthesis as essential processes in nonreplicating bacteria, and has aided in the development of compounds effective against hypoxic MTB (Boshoff et al., 2008; Bryk et al., 2008; Koul et al., 2008; Rao et al., 2008).”
BackgroundDrug resistant Tuberculosis: A review
Khawbung, J. L., Nath, D., & Chakraborty, S. (2021) · Comparative Immunology, Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2020.101574 · Cited by 248
Turning the respiratory flexibility of Mycobacterium tuberculosis against itself
Lamprecht, D. A., Finin, P. M., Rahman, M. A., Cumming, B. M., Russell, S. L., Jonnala, S. R., Adamson, J. H., & Steyn, A. J. C. (2016) · Nature Communications · doi:10.1038/ncomms12393 · Cited by 238
“BDQ inhibits ATP synthase (ETC Complex V) by binding to subunit c 11 , starving the bacteria of ATP 12,13 .”
Bactericidal mode of action of bedaquiline
Hards, K., Robson, J. R., Berney, M., Shaw, L., Bald, D., Koul, A., Andries, K., & Cook, G. M. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv054 · Cited by 226
Self-citationHaagsma, A. C., Abdillahi-Ibrahim, R., Wagner, M. J., Krab, K., Vergauwen, K., Guillemont, J., Andries, K., Lill, H., Koul, A., & Bald, D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01393-08 · Cited by 221
“This compound, which efficiently kills replicating as well as dormant mycobacteria (12, 18), is currently in clinical development in phase IIb trials in patients with multidrug-resistant tuberculosis.”
BackgroundSelf-citationBald, D., Villellas, C., Lu, P., & Koul, A. (2017) · mBio · doi:10.1128/mbio.00272-17 · Cited by 219
“culosis (17, 50), and killing by BDQ was correlated with an additional, pronounced drop”
BackgroundSelf-citationEnergetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T., & Berney, M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0015-2013 · Cited by 212
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F 1 F 0 -ATP synthase and inhibit ATP synthesis (109, 111, 112).”
BackgroundCook, G. M., Berney, M., Gebhard, S., Heinemann, M., Cox, R. A., Danilchanka, O., & Niederweis, M. (2009) · Advances in Microbial Physiology · doi:10.1016/s0065-2911(09)05502-7 · Cited by 204
“Koul et al. (2008) demonstrate that R207910 kills dormant M. tuberculosis as effectively as aerobically grown M. tuberculosis with the same target specificity.”
BackgroundTmc207: the First Compound of A New class of Potent Anti-Tuberculosis Drugs
Matteelli, A., Carvalho, A. C., Dooley, K. E., & Kritski, A. (2010) · Future Microbiology · doi:10.2217/fmb.10.50 · Cited by 204
Persisters and beyond: Mechanisms of phenotypic drug resistance and drug tolerance in bacteria
Kester, J. C., & Fortune, S. M. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.869543 · Cited by 202
“, 2008), presumably reflected in the increased potency on quiescent cells of certain drugs, like ATP-synthase-targeting diarylquinolones (Koul et al., 2008; Sala et al., 2010) and the lipopeptide daptomycin, which acts by depolarizing the”
BackgroundStructure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline
Guo, H., Courbon, G. M., Bueler, S. A., Mai, J., Liu, J., & Rubinstein, J. L. (2021) · Nature · doi:10.1038/s41586-020-3004-3 · Cited by 200
“b-δ (264-286) a (90-108) c (49-81) b' (30-48) b-δ (2-20) a (216-245) b' (30-63) c (53-80) BDQ-free BDQ-saturated”
Tasneen, R., Li, S.-Y., Peloquin, C. A., Taylor, D., Williams, K. N., Andries, K., Mdluli, K. E., & Nuermberger, E. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05293-11 · Cited by 194
“licating and nonreplicating organisms in vitro (5, 16, 26).”
BackgroundSelf-citationTargeting Antibiotic Tolerance, Pathogen by Pathogen
Meylan, S., Andrews, I. W., & Collins, J. J. (2018) · Cell · doi:10.1016/j.cell.2018.01.037 · Cited by 193
“Crucially, both engineered bacteriophages and phagemids have been validated as therapeutic strategies in murine infection models (Krom et al., 2015; Lu and Collins, 2009).”
Kalia, N. P., Hasenoehrl, E. J., Ab Rahman, N. B., Koh, V. H., Ang, M. L. T., Sajorda, D. R., Hards, K., Grüber, G., Alonso, S., Cook, G. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706139114 · Cited by 188
“The pmf is required for the survival of both replicating and nonreplicating (often referred to as dormant) mycobacteria (9, 10).”
BackgroundGuglielmetti, L., Le Du, D., Jachym, M., Henry, B., Martin, D., Caumes, E., Veziris, N., Metivier, N., Robert, J., for the MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort, et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu786 · Cited by 188
“In the mouse model, Bdq was associated with an effective sterilizing activity [8, 9].”
BackgroundThe chemotherapy of tuberculosis: past, present and future [State of the art]
Mitchison, D., & Davies, G. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0083 · Cited by 185
The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
Mdluli, K., Kaneko, T., & Upton, A. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021154 · Cited by 180
“PMF and ATP homeostasis are required by replicating and nonreplicating Mtb, under a variety of conditions (Koul et al. 2008; Rao et al. 2008), and efforts to target these processes include pathway screens using membrane particles, cell-based screens for ATP homeostasis disruptors, target-based screens, and repurposing…”
BackgroundEfflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy
Pule, C. M., Sampson, S. L., Warren, R. M., Black, P. A., van Helden, P. D., Victor, T. C., & Louw, G. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv316 · Cited by 173
Tuberculosis: The drug development pipeline at a glance
Villemagne, B., Crauste, C., Flipo, M., Baulard, A. R., Déprez, B., & Willand, N. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.033 · Cited by 172
“Interestingly, TMC207 is reported to be active against dormantmycobacteria [65].”
BackgroundEnergy Metabolism and Drug Efflux in Mycobacterium tuberculosis
Black, P. A., Warren, R. M., Louw, G., van Helden, P. D., Victor, T. C., & Kana, B. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02293-13 · Cited by 172
“Little is known about the energy requirements of mycobacteria during infection, although it has been demonstrated that ATP levels are important for survival in actively replicating as well as nonreplicating mycobacteria, demonstrating the importance of maintaining ATP levels under conditions of growth and survival (20…”
BackgroundInhibitors of Mycobacterium tuberculosis DosRST signaling and persistence
Zheng, H., Colvin, C. J., Johnson, B. K., Kirchhoff, P. D., Wilson, M., Jorgensen-Muga, K., Larsen, S. D., & Abramovitch, R. B. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2259 · Cited by 169
Totally drug‐resistant tuberculosis and adjunct therapies
Parida, S. K., Axelsson‐Robertson, R., Rao, M. V., Singh, N., Master, I., Lutckii, A., Keshavjee, S., Andersson, J., Zumla, A., & Maeurer, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12264 · Cited by 169
Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV
Goldberg, D. E., Siliciano, R. F., & Jacobs, W. R. (2012) · Cell · doi:10.1016/j.cell.2012.02.021 · Cited by 168
Kurosu, M., & Begari, E. (2010) · Molecules · doi:10.3390/molecules15031531 · Cited by 165
Adams, K. N., Szumowski, J. D., & Ramakrishnan, L. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu095 · Cited by 136
“Bedaquiline has been shown to be active against both replicating and nonreplicating bacteria in culture [8].”
Irwin, S. M., Prideaux, B., Lyon, E. R., Zimmerman, M. D., Brooks, E. J., Schrupp, C., Chen, C., Reichlen, M. J., Asay, B., Voskuil, M. I., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00127 · Cited by 165
Self-citationAntimycobacterial activity of lichen substances
Honda, N. K., Pavan, F. R., Coelho, R. G., Leite, S. R. D. A., Micheletti, A. C., Lopes, T. I. B., Misutsu, M. Y., Beatriz, A., Brum, R. L., & Leite, C. Q. F. (2009) · Phytomedicine · doi:10.1016/j.phymed.2009.07.018 · Cited by 159
“tuberculosis and that are able to kill the ‘‘dormant bacteria’’ in macrophages is therefore an urgent need (Quenelle et al. 2001; Suksamrarn et al. 2003; Caballeira 2008; Koul et al. 2008; Wagner and Ulrich-Merzenich 2009).”
BackgroundOverview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis
Chikhale, R. V., Barmade, M. A., Murumkar, P. R., & Yadav, M. R. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00281 · Cited by 158
Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase
Haagsma, A. C., Podasca, I., Koul, A., Andries, K., Guillemont, J., Lill, H., & Bald, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023575 · Cited by 149
Self-citationEnergetics of Pathogenic Bacteria and Opportunities for Drug Development
Cook, G. M., Greening, C., Hards, K., & Berney, M. (2014) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2014.08.001 · Cited by 147
Dhiman, R. K., Mahapatra, S., Slayden, R. A., Boyne, M. E., Lenaerts, A., Hinshaw, J. C., Angala, S. K., Chatterjee, D., Biswas, K., Narayanasamy, P., et al. (2009) · Molecular Microbiology · doi:10.1111/j.1365-2958.2009.06625.x · Cited by 146
“Two reports, published during the preparation of this manuscript, indicate that de novo ATP synthesis is indeed required for viability of NRP M. tuberculosis (Koul et al., 2008; Rao et al., 2008) as predicted by the transcriptional analysis reported here.”
BackgroundInfluentialSimple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis
Sala, C., Dhar, N., Hartkoorn, R. C., Zhang, M., Ha, Y. H., Schneider, P. A., & Cole, S. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00821-10 · Cited by 141
Targeting Phenotypically Tolerant Mycobacterium tuberculosis
Gold, B., & Nathan, C. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0031-2016 · Cited by 131
Cook, G. M., Hards, K., Dunn, E. A., Heikal, A., Nakatani, Y., Greening, C., Crick, D. C., Fontes, F. L., Pethe, K., Hasenoehrl, E., et al. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0014-2016 · Cited by 141
“tuberculosis cells are treated with TMC207 (12, 13), but these data do not explain cell death because mycobacterial cells can be depleted of ATP and yet remain viable (165).”
BackgroundInfluentialA Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
Fox, G. J., & Menzies, D. (2013) · Infectious Diseases and Therapy · doi:10.1007/s40121-013-0009-3 · Cited by 134
“Overall, the authors conclude that bedaquiline was possibly responsible for serious liver toxicity among patients in the Phase 2 studies [16], and suggest careful monitoring, particularly in patients with pre-existing liver disease and/or regular alcohol use.”
BackgroundTreatment of latent infection with Mycobacterium tuberculosis: update 2010
Leung, C. C., Rieder, H. L., Lange, C., & Yew, W. W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00079310 · Cited by 121
Borisov, V. B., Siletsky, S. A., Paiardini, A., Hoogewijs, D., Forte, E., Giuffrè, A., & Poole, R. K. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8039 · Cited by 121
“As a result, ATP synthesis is inhibited and intracellular ATP levels decrease significantly (193, 194).”
Tantry, S. J., Markad, S. D., Shinde, V. N., Bhat, J., Balakrishnan, G., Gupta, A. K., Ambady, A., Raichurkar, A. V., Kedari, C. K., Sharma, S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01358 · Cited by 131
ATP synthase in mycobacteria: Special features and implications for a function as drug target
Lü, P., Lill, H., & Bald, D. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.01.022 · Cited by 130
“also in the dormant state [18,25].”
Self-citationBedaquiline: A Novel Antitubercular Agent for the Treatment of Multidrug‐Resistant Tuberculosis
Worley, M. V., & Estrada, S. J. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1482 · Cited by 121
“12 Although ATP synthase is downregulated in dormant or nonreplicating mycobacteria due to decreased energy use, the ATP production by ATP synthase remains essential for mycobacterial survival.(12) Bedaquiline was found to be bactericidal with a slight increase in activity in these nonreplicating M.”
BackgroundNew tuberculosis drug leads from naturally occurring compounds
Quan, D. H., Nagalingam, G., Payne, R. J., & Triccas, J. A. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.12.024 · Cited by 116
“Bedaquiline targets ATP synthase by inhibiting the proton pumping mechanism(77) and has bactericidal effects on both active and non-replicating bacilli.(78) Early clinical trials showed bedaquiline to be safe and effective in increasing sputum culture conversion and reducing the treatment time required for sputum-nega…”
BackgroundAntibacterial activity of long-chain fatty alcohols against mycobacteria
Mukherjee, K., Tribedi, P., Mukhopadhyay, B., & Sil, A. K. (2012) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12043 · Cited by 114
Drugs in Development for Tuberculosis
Ginsberg, A. M. (2010) · Drugs · doi:10.2165/11538170-000000000-00000 · Cited by 113
“12mg/mL,([9,11,13]) and demonstrates marked bactericidal activity in both the acute and chronic mouse model of TB.”
BackgroundTargeting bacterial energetics to produce new antimicrobials
Hards, K., & Cook, G. M. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.11.001 · Cited by 113
Succinate Dehydrogenase is the Regulator of Respiration in Mycobacterium tuberculosis
Hartman, T., Weinrick, B., Vilchèze, C., Berney, M., Tufariello, J., Cook, G. M., & Jacobs, W. R. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004510 · Cited by 104
“nolone, Bedaquiline, a newly approved ATP-synthase inhibitor which is effective against dormant mycobacteria [8].”
BackgroundBedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
Field, S. K. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315582325 · Cited by 111
“Since bedaquiline has a long terminal half life, it should be discontinued 4–5 months before other drugs are stopped to prevent extended exposure of MTB to low levels of bedaquiline monotherapy which could increase the risk of resistance [CDC, 2013].”
BackgroundInfluentialHit Generation in TB Drug Discovery: From Genome to Granuloma
Yuan, T., & Sampson, N. S. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00602 · Cited by 110
Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis
Lee, B. S., Hards, K., Engelhart, C. A., Hasenoehrl, E. J., Kalia, N. P., Mackenzie, J. S., Sviriaeva, E., Chong, S. M. S., Manimekalai, M. S. S., Koh, V. H., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013207 · Cited by 97
Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
Machado, D., Girardini, M., Viveiros, M., & Pieroni, M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01367 · Cited by 106
“tuberculosis strains, both replicating and nonreplicating (Koul et al., 2008), and it shows an exceptional activity in vivo.”
BackgroundHaagsma, A. C., Driessen, N. N., Hahn, M.-M., Lill, H., & Bald, D. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.02123.x · Cited by 98
“Chemical inhibition of ATP synthesis by diarylquinolines strongly decreased cellular ATP levels, leading to bacterial killing (Koul et al., 2007, 2008; Rao et al., 2008).”
BackgroundSelf-citationNovel Antibiotics Targeting Respiratory ATP Synthesis in Gram-Positive Pathogenic Bacteria
Balemans, W., Vranckx, L., Lounis, N., Pop, O. I., Guillemont, J., Vergauwen, K., Mol, S., Gilissen, R., Motte, M., Lançois, D., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00273-12 · Cited by 103
“Previous experiments, aimed mainly at mycobacterial dormancy, have provided hints that despite absence of growth during a resting metabolic state, a minimal level of energy conversion within the bacterial cell is required for survival (25, 29).”
BackgroundSelf-citationGoldman, R. C. (2013) · Tuberculosis · doi:10.1016/j.tube.2013.09.003 · Cited by 102
Guillemont, J., Meyer, C., Poncelet, A., Bourdrez, X., & Andries, K. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.79 · Cited by 101
Self-citationTuberculous meningitis: The challenges
Murthy, J. M. K. (2010) · Neurology India · doi:10.4103/0028-3886.72178 · Cited by 100
Novel drugs against tuberculosis: a clinician's perspective
Olaru, I. D., von Groote-Bidlingmaier, F., Heyckendorf, J., Yew, W. W., Lange, C. G., & Chang, K. C. (2014) · European Respiratory Journal · doi:10.1183/09031936.00162314 · Cited by 97
Lü, P., Asseri, A. H., Kremer, M., Maaskant, J. J., Ummels, R., Lill, H., & Bald, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-20989-8 · Cited by 98
Self-citationRe-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline
Sarathy, J. P., Grüber, G., & Dick, T. (2019) · Antibiotics · doi:10.3390/antibiotics8040261 · Cited by 97
“BDQ carries out its anti-mycobacterial activity by inhibiting ATP synthesis, a process that is crucial to the growth of Mtb and to its survival in its non-growing dormant state [15,23,24].”
BackgroundNovel targets in M. tuberculosis: search for new drugs
Lamichhane, G. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.004 · Cited by 96
Honaker, R. W., Dhiman, R. K., Narayanasamy, P., Crick, D. C., & Voskuil, M. I. (2010) · Journal of Bacteriology · doi:10.1128/jb.00978-10 · Cited by 87
“Oxygen-limited, nonreplicating bacilli require electron flow via menaquinones, an intact proton motive force, and ATP production for survival (8, 24, 36).”
BackgroundDrug-resistance in Mycobacterium tuberculosis : where we stand
Mabhula, A., & Singh, V. (2019) · MedChemComm · doi:10.1039/c9md00057g · Cited by 96
Ionophoric effects of the antitubercular drug bedaquiline
Hards, K., McMillan, D. G. G., Schurig-Briccio, L. A., Gennis, R. B., Lill, H., Bald, D., & Cook, G. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803723115 · Cited by 95
Self-citationRespiratory ATP synthesis: the new generation of mycobacterial drug targets?
Bald, D., & Koul, A. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.01959.x · Cited by 94
Self-citationTargeting the Proteostasis Network for Mycobacterial Drug Discovery
Lupoli, T. J., Vaubourgeix, J., Burns-Huang, K. E., & Gold, B. S. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00231 · Cited by 94
A Mycobacterium tuberculosis Cytochrome bd Oxidase Mutant Is Hypersensitive to Bedaquiline
Berney, M., Hartman, T. E., & Jacobs, W. R. (2014) · mBio · doi:10.1128/mbio.01275-14 · Cited by 91
Mackenzie, J. S., Lamprecht, D. A., Asmal, R., Adamson, J., Borah, K., Beste, D. J. V., Lee, B. S., Pethe, K., Rousseau, S., Krieger, I. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19959-4 · Cited by 90
Sterilizing Activity of R207910 (TMC207)-containing Regimens in the Murine Model of Tuberculosis
Ibrahim, M., Truffot-Pernot, C., Andries, K., Jarlier, V., & Véziris, N. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200807-1152oc · Cited by 89
Self-citationRedox Biology of Tuberculosis Pathogenesis
Trivedi, A., Singh, N., Bhat, S. A., Gupta, P., & Kumar, A. (2012) · Advances in Microbial Physiology · doi:10.1016/b978-0-12-398264-3.00004-8 · Cited by 88
Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents
Lougheed, K. E. A., Osborne, S. A., SAXTY, B. A., Whalley, D. P., Chapman, T., Bouloc, N. S., Chugh, J., Nott, T. J., Patel, D., Rowlands, V., et al. (2011) · Tuberculosis · doi:10.1016/j.tube.2011.03.005 · Cited by 88
Grant, S. S., Kawate, T., Nag, P. P., Silvis, M. R., Gordon, K., Stanley, S. A., Kazyanskaya, E., Nietupski, R. M., Golas, A. J., FitzGerald, M. G., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4004817 · Cited by 88
Peterson, E. J. R., Ma, S., Sherman, D. R., & Baliga, N. S. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.78 · Cited by 88
Rising to the challenge: new therapies for tuberculosis
Wong, E. B., Cohen, K. A., & Bishai, W. R. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.05.002 · Cited by 87
Dheda, K. U. J., Cox, H. S., Esmail, A., Wasserman, S. A., Chang, K. C., & Lange, C. G. (2017) · Respirology · doi:10.1111/resp.13143 · Cited by 87
New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State
Muñiz, S. E. C., Anthony, R. M., Niemann, S., & Alffenaar, J. C. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-17 · Cited by 87
“Because ATP synthesis is an essential process in dormant cells, treatment of hypoxic nonreplicating bacilli with bedaquiline reduces the cell count more dramatically than isoniazid (an inhibitor of mycolic acid synthesis) (62).”
BackgroundStructure-Based Design of DevR Inhibitor Active against Nonreplicating Mycobacterium tuberculosis
Gupta, R. K., Thakur, T. S., Desiraju, G. R., & Tyagi, J. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900358q · Cited by 79
Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy
Chang, D. P. S., & Guan, X. L. (2021) · Metabolites · doi:10.3390/metabo11020088 · Cited by 82
Single-Cell Tracking Reveals Antibiotic-Induced Changes in Mycobacterial Energy Metabolism
Maglica, Ž., Özdemir, E., & McKinney, J. D. (2015) · mBio · doi:10.1128/mbio.02236-14 · Cited by 82
Biuković, G., Basak, S., Manimekalai, M. S. S., Rishikesan, S., Roessle, M. W., Dick, T., Rao, S. P. S., Hunke, C., & Grüber, G. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01039-12 · Cited by 81
“Chemical inhibition of ATP synthesis by diarylquinoline strongly decreased the cellular ATP level, leading to death in not only replicating but also nonreplicating persistent mycobacteria (5, 6).”
BackgroundCurrent development and future prospects in chemotherapy of tuberculosis
Nuermberger, E. L., Spigelman, M., & Yew, W. W. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01775.x · Cited by 80
Wang, M., Chan, E. W., Wan, Y., Wong, M. H. Y., & Chen, S. (2021) · Communications Biology · doi:10.1038/s42003-021-02612-1 · Cited by 77
Wallis, R. S., Jakubiec, W., Mitton‐Fry, M. J., Ladutko, L., Campbell, S. M., Paige, D., Silvia, A. M., & Miller, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030479 · Cited by 77
“Shorter times to onset of action of TMC207 have been reported under hypoxic conditions [15] and in intracellular infection [16] as compared to aerobic broth culture.”
BackgroundPereiro, J. E., Sánchez‐Montalvá, A., Aznar, M. L., & Espiau, M. (2022) · Medicina · doi:10.3390/medicina58020188 · Cited by 76
Chaudhari, K., Surana, S. J., Jain, P., & Patel, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.034 · Cited by 76
Zhang, T., Li, S., Williams, K. N., Andries, K., & Nuermberger, E. L. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0397oc · Cited by 75
“Drug doses (in mg/kg) for 5/7 regimens were as follows: INH (10), RIF (10), PZA (150), RPT (10), and TMC (25 or 12.”
MethodSelf-citationBiological Properties of 1H-1,2,3- and 2H-1,2,3-Triazoles
da Silva, F. D. C., Cardoso, M. F. D. C., Ferreira, P. G., & Ferreira, V. F. (2014) · Topics in heterocyclic chemistry · doi:10.1007/7081_2014_124 · Cited by 75
Challenges and Opportunities in Developing Novel Drugs for TB
Kaneko, T., Cooper, C. B., & Mdluli, K. E. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.115 · Cited by 74
Sharma, D., Kumar, B., Lata, M., Joshi, B., Venkatesan, K., Shukla, S., & Bisht, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139414 · Cited by 73
Antitubercular pharmacodynamics of phenothiazines
Warman, A. J., Rito, T., Fisher, N. E., Moss, D. M., Berry, N. G., O’Neill, P. M., Ward, S. A., & Biagini, G. A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks483 · Cited by 71
The chemical biology of new drugs in the development for tuberculosis
Barry, C. E., & Blanchard, J. S. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.04.008 · Cited by 68
Metadata
- Authors
- Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Göhlmann, H. W. H., Willebrords, R., Poncelet, A., Guillemont, J., Bald, D., & Andries, K.
- Affiliations
- Johnson & Johnson (France) (FR)
- Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Koul, Anil
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 283
- Issue
- 37
- Pages
- 25273-25280
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2164282552
- Cited by
- 364
- References
- 31
- Citations by year
- 2026: 16 · 2025: 17 · 2024: 10 · 2023: 19 · 2022: 16 · 2021: 22 · 2020: 23 · 2019: 25 · 2018: 17 · 2017: 25 · 2016: 15 · 2015: 20 · 2014: 29 · 2013: 20 · 2012: 22
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4495 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- diarylquinolines, bedaquiline, Mycobacterium tuberculosis, dormant mycobacteria, latent tuberculosis infection, ATP synthase inhibition, ATP homeostasis, bactericidal activity, tuberculosis drug targets
- MeSH terms
- Adenosine Triphosphate, Antitubercular Agents, Homeostasis, Models, Biological, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Nitric Oxide, Oxygen, Quinolines, RNA, Messenger, Time Factors, Gene Expression Regulation, Bacterial, Mycobacterium smegmatis, Mitochondrial Proton-Translocating ATPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.